SCHEMBL208062

SCHEMBL208062

Fc1ccc2[c]n[nH]c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 7/20 0.40
AHR P35869 2/20 0.36
KDM4E B2RXH2 1/20 0.36
DAO P14920 1/20 0.34
METAP2 P50579 1/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
GPR84 Q9NQS5 1/20 0.32
MAPK1 P28482 1/20 0.32
MAPK6 Q16659 1/20 0.32
IDO1 P14902 2/20 0.32
MAP2K7 O14733 1/20 0.31
ITK Q08881 1/20 0.31
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207457 0.85 METAP2 (0.38) MAP2K4AHRKDM4EDAOMETAP2
SCHEMBL6217817 0.75 MAPT (0.42) KDM4EMAPK1ACHE
SCHEMBL208155 0.75 DYRK1A (0.42) AHRMETAP2CDK2CDK5
SCHEMBL2435236 0.75 METAP2 (0.47) MAP2K4METAP2MAPK1MAPK6
SCHEMBL2441098 0.74 GPR84 (0.31) GPR84
SCHEMBL406467 0.68 MAPT (0.50) DAO
SCHEMBL7579630 0.64 MEN1 (0.44) KDM4EACHE
SCHEMBL208707 0.64 AHR (0.42) MAP2K4AHRKDM4EDAOALPL
SCHEMBL14485029 0.63 GPR84 (0.42) AHRGPR84MAPK1
SCHEMBL612070 0.62 GPR84 (0.32) DAOGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048910-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2022-02-17 US claimed
EP-3946345-A1 METHODS OF TREATING NEUROPATHIC PAIN Intra-Cellular Therapies, Inc. (US) 2022-02-09 EP claimed
CN-113905737-A Method of treating neuropathic pain 细胞内治疗公司 2022-01-07 CN claimed
EP-3914235-A2 METHODS OF TREATING ADDICTION Intra-Cellular Therapies, Inc. (US) 2021-12-01 EP claimed
EP-3897621-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2021-10-27 EP claimed
CN-113329742-A Method for treating addiction 细胞内治疗公司 2021-08-31 CN claimed
WO-2020206391-A1 METHODS OF TREATING NEUROPATHIC PAIN INTRA-CELLULAR THERAPIES, INC. (US) 2020-10-08 WO claimed
WO-2020154519-A2 METHODS OF TREATING ADDICTION INTRA-CELLULAR THERAPIES, INC. (US) 2020-07-30 WO claimed
WO-2020132605-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2020-06-25 WO claimed
EP-0700396-A1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1996-03-13 EP claimed
US-5478845-A Inhibit dopamine or 5-hydroxytryptamine receptor binding NOVO NORDISK A/S (DK) 1995-12-26 US claimed
WO-1994027994-A1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-12-08 WO claimed
CN-118105390-A Method for treating addiction 细胞内治疗公司 2024-05-31 CN disclosed
CN-117440774-A Biomarkers of age-related macular degeneration 倍亮生物有限责任公司 2024-01-23 CN disclosed
WO-2023069880-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. (US) 2023-04-27 WO disclosed
US-20220184072-A1 METHODS OF TREATING NEUROPATHIC PAIN INTRA-CELLULAR THERAPIES, INC. 2022-06-16 US disclosed
US-5478845-A Inhibit dopamine or 5-hydroxytryptamine receptor binding NOVO NORDISK A/S (DK) 1995-12-26 US disclosed
WO-1994027992-A1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-12-08 WO disclosed
WO-1994027994-A1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-12-08 WO disclosed
WO-1994027994-A1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220184072-A1 METHODS OF TREATING NEUROPATHIC PAIN GAP43, OPRK1, CNR2 MAP2K4 3392/4885AHR 4251/4885KDM4E 3601/4885
US-20220048910-A1 ORGANIC COMPOUNDS OPRD1, OPRM1, HTR2C MAP2K4 1692/4885AHR 606/4885KDM4E 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.